Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice
- PMID: 32424919
- DOI: 10.1111/apt.15652
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice
Comment in
-
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply.Aliment Pharmacol Ther. 2020 Jun;51(11):1209-1210. doi: 10.1111/apt.15735. Aliment Pharmacol Ther. 2020. PMID: 32424928 No abstract available.
Comment on
-
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076. doi: 10.1111/apt.15514. Epub 2019 Oct 9. Aliment Pharmacol Ther. 2019. PMID: 31599001 Free PMC article.
References
REFERENCES
-
- Sandborn WJ, Panés J, Sands BE, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019;50:1068-1076.
-
- Teixeira FV, Damião AOMC, Kotze PG. Tofacitinib in the management of ulcerative colitis refractory to anti-TNF and anti-integrin therapies. Arq Gastroenterol. 2018;55:198-200.
-
- Sands BE, Taub PR, Armuzzi A, et al. Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18:123-132.e3.
-
- Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1450-1459.
-
- Seyahi E. Venous involvement in inflammatory disorders. Curr Opin Rheumatol. 2020;32:29-34.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical